Abstract: The disclosure provides methods of treating myasthenia gravis (MG) in a pediatric subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (CS). In son embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

Abstract: A door control device includes: an electric motor control unit configured to drive, in response to a closing command for closing a door that is driven to be opened and closed by an electric motor, the electric motor; a door closed state detection unit configured to detect a closed state of the door; and a lock command output unit configured to output a lock command to lock a locking device of the door, upon the closed state being detected when a predetermined waiting time has passed after the electric motor was driven by the electric motor control unit in response to the closing command and the closed state was detected by the door closed state detection unit.

Abstract: A door control device includes: a speed control unit configured to perform speed control of an electric motor that drives a door; a speed detection unit configured to detect a speed of the door; and an obstruction detection unit configured to detect obstruction between the door and a door pocket, upon a value of the speed of the door detected by the speed detection unit decreasing by a first predetermined value or more with respect to a speed command value in the speed control during a door opening operation of the door.

Abstract: A distance-measuring system includes: a first ranging sensor; a second ranging sensor that covers a detection range more limited than a detection range covered by the first ranging sensor and has resolution higher than resolution of the first ranging sensor; and an image processing device. The image processing device includes: a machine detector that detects a position of a mobile machine, based on a first sensed result obtained by the first ranging sensor; a sensor controller that controls a detection position to be detected by the second ranging sensor to detect the position of the mobile machine which has been detected; and a safety determiner that controls the mobile machine, based on a second sensed result obtained by the second ranging sensor.

Abstract: A protrusion is formed on a facing surface which is integral with a shaft of a hinge mechanism. The protrusion has a tip that is in contact with an end surface of the engagement portion when the first member and the second member swing relative to each other, so that displacement of the second member along the lengthwise direction of the shaft is restricted. A state immediately after the engagement portion is engaged with the shaft is referred to as an initial engagement state. In the initial engagement state, the protrusion is situated at a position beyond a center of the shaft when viewed in a direction of engaging the engagement portion with the shaft, and the end surface of the engagement portion is separated from the tip of the protrusion.

Abstract: An aligning and conveying apparatus includes a rotating disk having a bottom wall, a first ring having a first circumferential wall, a second ring having a second circumferential wall. First and second conveying parts are respectively provided in upper parts of the first and second circumferential walls. In the rotating disk and the first ring, the bottom wall is positioned lower than the first conveying part to form a retaining space for retaining preparations inside the first ring. The respective rotational axes are relatively inclined such that the preparations move from the bottom wall to the first conveying part at a first delivery position. In the first and second rings, the first conveying part is positioned lower than the second conveying part, and the respective rotational axes are relatively inclined such that the preparations move from the first conveying part to the second conveying part at a second delivery position.

Abstract: Provided is a mobile terminal testing apparatus capable of executing a test for putting any pseudo base station out of service during state transition, such as during handover or during position registration. A mobile terminal testing apparatus includes a plurality of pseudo base station units 18-1, 18-2, and 18-3 that simulate a plurality of base stations, and a scenario processing unit 17 that controls the pseudo base station units 18-1, 18-2, and 18-3 in compliance with a set scenario to execute a test. The scenario processing unit 17 puts the pseudo base station units 18-1, 18-2, and 18-3 set as a base station executing an out-of-service test out of service in a case where a message set as a message to execute the out-of-service test is transmitted from the pseudo base station units 18-1, 18-2, and 18-3 set as a base station transmitting the message to execute the out-of-service test.

Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child having HPP) exhibiting physical impairments, disability in activities of daily living (ADL), pain, and/or delayed motor development by administering a soluble alkaline phosphatase (sALP) to the patient.

Abstract: Provided is a pharmaceutical formulation transporting device capable of easily ensuring a large exposed area of a solid pharmaceutical formulation during transport. A pharmaceutical formulation transporting device 10 comprises a first pulley 11, a second pulley 12, and a plurality of endless transport belts 13, 14 wound around the first pulley 11 and the second pulley 12, wherein the plurality of transport belts 13, 14 are disposed so as to be capable of holding a solid pharmaceutical formulation between respective first side surfaces.

Abstract: Provided is an aligning and conveying apparatus 1 comprising a rotating disk 10 having a disk-shaped bottom wall 11 and supported so as to be rotatable, a first ring 20 having a first circumferential wall 21 surrounding the bottom wall 11 and supported so as to be rotatable, and a second ring 30 having a second circumferential wall 31 surrounding the first circumferential wall 21 and supported so as to be rotatable, wherein a first conveying part 91 and a second conveying part 92 are respectively provided in upper parts of the first circumferential wall 21 and the second circumferential wall 31, in the rotating disk 10 and the first ring 20, the bottom wall 11 is positioned lower than the first conveying part 91 so as to form a retaining space S for retaining preparations P inside the first ring 10, and the respective rotational axes are relatively inclined such that the preparations P move from the bottom wall 11 to the first conveying part 91 at a first delivery position P1, and in the first ring 20 and the

Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., adolescent or adult having HPP) exhibiting physical impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient.

Abstract: The present invention relates to an optical laminate capable of providing a display panel in which worsening of visibility owing to reflected colors is suppressed. Furthermore, the present invention provides a display panel including the aforementioned optical laminate; a display device including the foregoing optical laminate; and an antireflection layer, a circular polarizing plate, a retardation plate, and a polarizing plate, each of which is used for the aforementioned display panel. The optical laminate includes a circular polarizing plate having a retardation plate and a polarizer, and an antireflection layer having a surface reflectance of 2% or less, wherein the antireflection layer is provided on the polarizer side of the circular polarizing plate; and L* of light incident from the antireflection layer side in the SCI mode is 20 or less, and a saturation is 20 or less.

Abstract: Provided are methods for clinical treatment of generalized myasthenia gravis (gMG) using an anti-C5 antibody or antigen binding fragment thereof.

Abstract: The disclosure features methods for treating hypophosphatasia (HPP) in a patient (e.g., a child or an adolescent having HPP) exhibiting gait impairments or decreased walking ability by administering a soluble alkaline phosphatase (sALP) to the patient and assessing improvement in the gait impairment using a modified Performance-Oriented Mobility Assessment-Gait (mPOMA-G) analysis and score.

Abstract: A liquid crystal display panel includes: a liquid crystal cell that has a liquid crystal layer; first and second linear polarizers arranged on an observer side and a back surface side of the liquid crystal cell; a first retardation layer arranged between the first linear polarizer and the liquid crystal layer; and a second retardation layer arranged between the first retardation layer and the second linear polarizer.

Abstract: A liquid crystal display panel includes: a liquid crystal cell that has a liquid crystal layer; first and second linear polarizers arranged on an observer side and a back surface side of the liquid crystal cell; a first retardation layer arranged between the first linear polarizer and the liquid crystal layer; and a second retardation layer arranged between the first retardation layer and the second linear polarizer.

Abstract: A door opening/closing device includes: an opening/closing bar attached to a door, which is actuated by a motor and is used for opening and closing the door; a door closing state detecting part configured to detect whether the door is in a closed state; a locking device configured to lock and unlock the door; a lock pin capable of being moved to a locked position or an unlocked position by the locking device; an engaging member attached to the opening/closing bar, which includes an engaging part configured to engage with the lock pin moved to the locked position; a first spring provided between the opening/closing bar and the engaging member; and a locking control unit configured to cause the locking device to lock the door when the closed state is detected by the door closing state detecting part.

Abstract: A door control device includes: a speed control unit configured to perform speed control of an electric motor that drives a door; a speed detection unit configured to detect a speed of the door; and an obstruction detection unit configured to detect obstruction between the door and a door pocket, upon a value of the speed of the door detected by the speed detection unit decreasing by a first predetermined value or more with respect to a speed command value in the speed control during a door opening operation of the door.

Abstract: Provided is a pharmaceutical formulation transporting device capable of easily ensuring a large exposed area of a solid pharmaceutical formulation during transport. A pharmaceutical formulation transporting device 10 comprises a first pulley 11, a second pulley 12, and a plurality of endless transport belts 13, 14 wound around the first pulley 11 and the second pulley 12, wherein the plurality of transport belts 13, 14 are disposed so as to be capable of holding a solid pharmaceutical formulation between respective first side surfaces.

Abstract: A door opening/closing device includes: an opening/closing bar attached to a door, which is actuated by a motor and is used for opening and closing the door; a door closing state detecting part configured to detect whether the door is in a closed state; a locking device configured to lock and unlock the door; a lock pin capable of being moved to a locked position or an unlocked position by the locking device; an engaging member attached to the opening/closing bar, which includes an engaging part configured to engage with the lock pin moved to the locked position; a first spring provided between the opening/closing bar and the engaging member; and a locking control unit configured to cause the locking device to lock the door when the closed state is detected by the door closing state detecting part.